Borderline Personality Disorder Medication

No medication is approved to treat borderline personality disorder, and talk therapy comes first. Used carefully, certain drugs can still ease specific symptoms like anger, mood swings, or impulsivity as part of a wider plan.

Jessica Miller is the Content Manager of Addiction HelpWritten by
Kent S. Hoffman, D.O. is a founder of Addiction HelpMedically reviewed by Kent S. Hoffman, D.O.
Last updated

Battling addiction & ready for help?

Find Treatment Now

How Medication Fits Into Borderline Personality Disorder Treatment

If you are looking into medication for borderline personality disorder, one fact settles a lot of fear up front. No drug treats BPD itself, and structured talk therapy, not medication, is the first-line treatment[1]. Medication has a real but supporting role, and most people with BPD improve a great deal over time[2].

That supporting role is worth understanding clearly, because what gets prescribed and what the evidence supports do not always line up. Used with care and aimed at specific symptoms, certain medications can ease parts of the picture like anger, mood swings, or impulsivity, as one piece of a wider plan[3].

Thinking about self-harm or suicide? You can get help right now. Call or text 988, any time, free and confidential.
If you are thinking about suicide or about to hurt yourself, call or text 988 (the Suicide and Crisis Lifeline) for free, confidential support, any time.

What to do in the moment:

  • Reach a person now. Call or text 988, or text HOME to 741741 (Crisis Text Line). You do not have to be sure you are in danger to reach out.
  • Put space between you and the means of harm. Move to another room, hand sharp objects or pills to someone you trust, and stay near other people if you can.
  • Ride out the wave. Urges to self-harm tend to peak and pass within minutes. Cold water on the face, hard exercise, or one phone call can carry you through the spike.
  • If someone has seriously hurt themselves or taken an overdose, call 911.

Find mental health and addiction treatment that fits →

AddictionHelp.com Fast Facts
  • No drug is approved for BPD. No medication is approved by regulators to treat BPD itself, yet up to 96 percent of people with the diagnosis are prescribed at least one[4].
  • Therapy comes first. Structured psychotherapy is the first-line treatment and the part that does the central work; medication only supports it[1].
  • Drugs target symptoms, not the disorder. Where medication helps, it eases specific clusters like anger or mood instability rather than BPD as a whole[5].
  • The evidence is thin. Most BPD drug trials are small and short, and the certainty of the evidence is mostly low to very low[4].
  • Benzodiazepines are best avoided. In a large real-world study, benzodiazepine use was linked to worse outcomes, not better ones[6].

Why No Drug Treats BPD on Its Own

BPD is a disorder of emotion regulation, identity, and relationships built up over years, and no pill reorganizes that. Reviews of every drug class reach the same conclusion, that no medication treats the global picture of BPD[7]. What medication can do is turn the volume down on particular symptoms while the deeper work happens in therapy.

This is the reverse of how many conditions are handled, where a drug is the main event. For BPD, practice guidelines around the world put psychotherapy first and place medication in a supporting role only[1]. Knowing that order protects you from expecting a prescription to do a job it cannot.

Medication Supports Therapy, It Does Not Replace It

Medication and therapy are not rivals. Combining the two can help specific symptom dimensions, especially the ones that respond slowly to talk therapy alone, so a well-chosen drug can make the work of therapy easier to engage with[7]. The aim is to support recovery, not to stand in for it.

The reverse matters too. A prescription is never a reason to skip therapy, because the structured psychotherapies are what reduce the symptoms that hurt most, including self-harm and suicidal behavior[8]. Medication is the scaffold; therapy is the building.

What Off-Label Prescribing Means for BPD

Off-label is not the same as untestedOff-label means regulators have not formally approved a drug for this exact use, not that it is unsafe or unstudied. Many standard treatments across medicine are off-label. It calls for clear goals and review, not alarm.

Almost every medication used for BPD is prescribed off-label, a word that sounds alarming until you know what it means. Off-label simply means a drug is being used for a purpose regulators have not formally signed off on, which is legal, routine across medicine, and not the same as experimental[5].

Why Almost Everyone With BPD Is Prescribed Something

The gap between what is approved and what is prescribed is striking. No drug is approved for BPD, yet up to 96 percent of people with the diagnosis take at least one psychiatric medication, often several at once[4]. Prescribing is the norm, not the exception.

The main driver is not BPD itself but the conditions that travel with it. Comorbidity, such as depression, anxiety, or a substance problem, is the most common reason medication and polypharmacy get started[9]. Much prescribing is really aimed at those companions, a distinction that matters when you weigh what a drug is actually for.

The Risk of Stacking Too Many Drugs

Because prescriptions tend to accumulate one symptom at a time, many people end up on several psychiatric drugs for long stretches[10]. Each addition is understandable on its own, yet the total can become a tangle that is hard to evaluate and easy to keep refilling.

Polypharmacy is something experts increasingly counsel against, and reviews advise keeping the number of drugs low and the goals clear[7]. Encouragingly, prescribing patterns are shifting, with overall medication use and benzodiazepine use falling over the past two decades as the field grows more cautious[11].

Matching Medication to Symptom Domains

Because no drug treats BPD as a whole, prescribing works best when it targets a specific symptom domain. Researchers group BPD symptoms into three clusters, and different drug classes line up with different clusters[12].

The Three Symptom Clusters Medication Targets

The three domains are affective dysregulation (mood swings, anger, emotional pain), impulsive-behavioral dyscontrol (impulsivity, self-harm, aggression), and cognitive-perceptual symptoms (suspiciousness, dissociation, brief stress-related distortions)[12]. A prescriber who names the target you are aiming at is doing it right.

Across trials, mood stabilizers and antipsychotics show the most promise for affective dysregulation and impulsive-behavioral dyscontrol, while antipsychotics also reach the cognitive-perceptual cluster[12]. Antidepressants, by contrast, do little beyond the mood symptoms they are designed for[12].

Symptom domain Medication classes most studied What the evidence suggests
Anger, hostility, aggression Topiramate, lamotrigine, aripiprazole The strongest signals in network analysis; topiramate carried the highest certainty, lamotrigine and aripiprazole moderate[3]
Affective instability (mood swings) Mood stabilizers, atypical antipsychotics Moderate benefit for the mood cluster, though trials are small and short[12]
Impulsivity and self-harm Mood stabilizers such as carbamazepine, atypical antipsychotics Some benefit for impulsivity, but at low certainty[3]
Cognitive-perceptual (suspiciousness, dissociation) Atypical antipsychotics The class that reaches this cluster, at low certainty[13]
Co-occurring depression or anxiety SSRIs, sometimes anticonvulsants Aimed at the comorbidity, with little direct effect on BPD itself[13]

How Strong the Evidence Really Is

The quality of this evidence deserves a clear look. The most recent network meta-analysis pooled 35 trials and about 2,551 participants across 26 different treatments, and many of those trials carried a low or moderate risk of bias[3]. Even the better-supported findings rest on a fairly thin base.

Independent reviews using formal grading reach the same verdict, that the certainty of evidence for BPD medications is mostly low to very low[4]. That does not mean nothing works. It means benefits are modest and specific, and a drug deserves a fair trial with a clear target and a frank review of whether it helped.

Mood Stabilizers and Anticonvulsants

Promising in small trials, flat in big onesSeveral BPD drugs looked helpful in short, small studies, then showed no benefit once tested in a large, long trial. That pattern is exactly why a single encouraging study is never the last word.

Mood stabilizers, a group of anticonvulsant drugs borrowed from epilepsy and bipolar care, are among the better-studied options for BPD. They tend to be aimed at anger and impulsivity rather than at low mood[14].

What Mood Stabilizers Can Help

In meta-analysis, mood stabilizers as a group showed a large effect on anger, one of the most reliable medication signals in BPD[14]. The newest network analysis points the same way, naming topiramate and lamotrigine among the most effective drugs for reducing hostility, aggression, and anger[3].

Carbamazepine has shown some benefit for impulsivity, though at low certainty, and topiramate carried the highest grade of evidence of any drug for anger in that analysis[3]. These are targeted gains, not a fix for BPD, and they come with the usual need to watch for side effects.

Why the Lamotrigine Story Is a Caution

Lamotrigine shows why caution matters. Early, smaller studies suggested it might reduce anger and BPD symptoms[3]. Then it was put to a larger test.

A multicenter randomized trial followed 276 people with BPD for a year on either lamotrigine or placebo. There was no difference between the groups in BPD symptom severity or in any secondary outcome, and the drug added cost without benefit[15]. One large, well-run study can overturn a hopeful picture, which is why the strength of the evidence, not just its direction, matters.

Antipsychotics for Specific Symptoms

Side effects are part of the mathAntipsychotics can bring weight gain, restlessness, and a movement side effect called akathisia. None of that means avoid them, but it does mean the benefit for your target symptom should clearly outweigh the cost, reviewed over time.

Atypical antipsychotics, also called second-generation antipsychotics, are the other well-studied class, and their use in BPD has risen over the past two decades[11]. They are aimed at particular symptom clusters rather than at BPD as a whole[12].

Where Atypical Antipsychotics Help Most

The clearest signal is for anger and the cognitive-perceptual cluster. Antipsychotics show a moderate effect on anger, and aripiprazole stands out with a notably larger effect than other drugs in its class[14]. They are also the class that reaches suspiciousness and dissociation, though at low certainty[13].

Aripiprazole has the most encouraging profile here. A systematic review found it reduced anxiety, depression, anger, hostility, and overall clinical severity in BPD[16], and the network analysis ranked it among the most effective drugs for hostility and anger[3]. That same review cautioned that its trials were small and at considerable risk of bias[16].

Weighing Benefits Against Side Effects

Symptom relief always has to be set against tolerability. Aripiprazole’s reported side effects include headache, insomnia, restlessness, tremor, and akathisia[16]. Other atypicals can add weight gain and metabolic changes that matter over the long run.

This is also where a large real-world study gives pause. Tracking more than 17,000 people with BPD, antipsychotic use was associated with a higher risk of psychiatric hospitalization, not a lower one, a reminder that average effects hide wide variation between people[6]. The takeaway is not never, but to watch closely and keep checking whether it is truly helping.

Antidepressants and the Comorbidity Question

Treating your depression is not treating your BPDAn antidepressant can genuinely help a co-occurring depression while doing little for the BPD underneath. Feeling some relief does not mean the medicine is fixing the personality-level symptoms, and that distinction guides what to expect.

Antidepressants, especially SSRIs, are among the most prescribed drugs in BPD, with around three in four patients on one in some clinics[11]. Yet they are the class with the weakest direct evidence for BPD itself.

SSRIs Treat Comorbidities, Not BPD Itself

When researchers look specifically at BPD symptoms, antidepressants mostly come up short. A meta-analysis of symptom dimensions found they did little beyond the mood symptoms they are built for[12]. A secondary analysis of the Cochrane trials found no significant antidepressant effect even on co-occurring symptoms, at very low certainty[13].

Where they earn their place is the company BPD keeps. Depression, anxiety, and other conditions co-occur often, and treating a clear comorbid disorder is a legitimate, common reason to prescribe[9]. The key is naming the actual target, so an SSRI is understood as treatment for depression rather than a treatment for BPD.

Treating Depression and Anxiety Alongside BPD

Targeting comorbidity well takes some care. Recommendations differ widely between guidelines, and the same drug class can look helpful for one companion condition and useless for another[9]. Anticonvulsants, for instance, showed some effect on depressive and anxious symptoms in the Cochrane re-analysis, while antidepressants did not[13].

None of this replaces the central work. Medication for a comorbidity should sit alongside BPD-specific psychotherapy, not stand in for it, and it works best reviewed regularly so it does not quietly become permanent[9]. A drug that is no longer helping is a drug to reconsider.

Medications to Use With Caution or Avoid

Fast relief, slower harmBenzodiazepines can calm a crisis in the moment, which is exactly why they are easy to lean on. Over time they can deepen impulsivity and dependence, so short-term relief can buy longer-term trouble.

Some prescribing carries more risk than benefit, and a few patterns deserve plain flags. The clearest involves benzodiazepines, the sedating anti-anxiety class that includes alprazolam, lorazepam, and diazepam, which are commonly prescribed in BPD despite real concerns[9].

Why Benzodiazepines Are Usually the Wrong Choice

Two lines of evidence converge here. In the network meta-analysis, alprazolam was among the drugs with only low-certainty evidence that should not be prioritized in BPD[3]. In a large real-world study, benzodiazepine use carried the strongest link of any class to psychiatric rehospitalization and to all-cause hospitalization or death[6].

There are real reasons behind the signal. Benzodiazepines can reduce inhibition, which may worsen impulsivity and self-harm in a disorder already marked by both, and they carry a clear risk of dependence[9]. For most people with BPD they are best limited to rare, short-term use under close supervision, if used at all.

When a Prescription Should Be Reviewed or Stopped

Stopping a medication can be as important as starting one. A large share of BPD prescribing accumulates without clear benefit, and reviews urge prescribers to limit polypharmacy and reconsider drugs that are not earning their place[7]. Deprescribing, the planned tapering of a drug that is not helping, is a legitimate part of good care.

The encouraging trend is that the field is already moving this way, with overall medication and benzodiazepine use declining as cautious, symptom-targeted prescribing replaces reflexive habits[11]. If you are on several psychiatric drugs and unsure why, that is a fair and useful question to bring to your prescriber.

Medication, Addiction, and Substance Use

BPD and substance use overlap heavily, and the combination shapes prescribing in important ways. About 78 percent of people with BPD develop a substance-related disorder at some point, so this is the common situation, not a rare complication[17].

Why Benzodiazepines and Addiction Are a Dangerous Mix

When a substance problem is in the picture, the case against benzodiazepines gets stronger. They carry their own dependence and misuse potential, which is hazardous for anyone with an addiction history, and the real-world data already link them to worse outcomes in BPD[6]. Many prescribers avoid them entirely in this group.

Stimulants and other controlled medications call for the same care and clear communication. The safest plan names any history of substance use up front, so a prescriber can choose drugs with lower misuse potential and watch for interactions[9].

One Plan When BPD and Addiction Overlap

The deeper point is that two problems do best with one integrated plan. The same unbearable emotions often drive both the BPD symptoms and the substance use, so care that treats them together tends to work better than treating them in sequence[17]. Medication is a small part of that plan, with therapy and skills at the center.

If substances have become part of how you cope with these symptoms, that is common, and it is treatable. A confidential search can match you with programs that handle mental health and addiction at the same time through a single treatment finder, and the fuller picture of co-occurring care is laid out on the main borderline personality disorder overview.

Getting Help and Talking to a Prescriber

Medication is one tool among several, and using it well comes down to good questions and the right order of operations: therapy first, medication aimed at clear targets[1], and regular review of whether it is helping[9].

Questions Worth Asking Before Starting a Medication

A few direct questions will tell you most of what you need to know about a proposed prescription:

  • What specific symptom or co-occurring condition is this aimed at, and how will we know if it is working?
  • Is this for my BPD itself, or for something alongside it like depression or anxiety?
  • What are the main side effects, and how will we monitor them?
  • How long should I expect to take it, and when will we review whether to continue?
  • Could this interact with alcohol or any substances I use?

These are not confrontational questions; they are the marks of a good prescribing relationship. A clinician who welcomes them, names a clear target, and plans to review the drug is practicing exactly the kind of careful, symptom-focused prescribing the evidence supports[9].

Your First Step Toward Treatment That Works

The outlook is far better than the diagnosis’s reputation suggests. Across long-term studies, 50 to 70 percent of people no longer meet the criteria for BPD years later, with the impulsive and self-harming symptoms easing earliest[2]. Recovery is the usual course, and treatment, led by therapy, is what gets people there[8].

You do not need to have it all figured out to begin. A primary care doctor, a community mental health center, or a treatment line can point you toward an assessment and the right level of care[18]. That includes help finding therapy and a prescriber who treats medication as the support it is.

Bring the patterns you have noticed and any history of substance use, because that information shapes the safest plan. Help that fits your situation exists, and most people who reach for it get better.

Whatever brought you here, BPD is treatable and getting better is the most likely outcome. Free, confidential help is available right now.

Find treatment that fits your life →

Frequently asked questions

Is There a Medication for Borderline Personality Disorder?

No medication is approved by regulators to treat BPD itself, and structured psychotherapy, not medication, is the first-line treatment[1]. Drugs are used off-label and aimed at specific symptoms like anger, mood swings, or impulsivity, or at co-occurring conditions such as depression[5]. Even so, up to 96 percent of people with BPD are prescribed at least one psychiatric medication[4]. Used with clear goals and regular review, medication can support recovery, but it does not replace therapy.

What Is the Best Medication for BPD?

There is no single best drug, because none treats BPD as a whole[7]. The right choice depends on the symptom you are targeting. For anger, hostility, and aggression, topiramate, lamotrigine, and aripiprazole have the strongest evidence, with topiramate carrying the highest certainty[3]. Mood stabilizers and atypical antipsychotics show the most promise for mood instability and impulsivity, while antidepressants mainly help a co-occurring depression or anxiety rather than BPD itself[12].

Do Antidepressants Help Borderline Personality Disorder?

Antidepressants do little for BPD itself. A meta-analysis of symptom dimensions found they did not help beyond the mood symptoms they are designed for[12], and a re-analysis of the Cochrane trials found no significant antidepressant effect even on co-occurring symptoms, at very low certainty[13]. They are still widely prescribed, mainly to treat a co-occurring depression or anxiety disorder rather than BPD[9]. The key is knowing which target a prescription is really for.

Why Should People With BPD Avoid Benzodiazepines?

Benzodiazepines such as alprazolam are tempting for acute distress but tend to make things worse over time. In the most recent network meta-analysis, alprazolam had only low-certainty evidence and was flagged as a drug that should not be prioritized[3]. A large real-world study linked benzodiazepine use to the highest risk of psychiatric rehospitalization and of all-cause hospitalization or death among BPD medications[6]. They also carry dependence risk, which is especially hazardous alongside addiction[9].

Can Medication Replace Therapy for BPD?

No. Psychotherapy is the first-line treatment and the part that reduces the symptoms that hurt most, including self-harm and suicidal behavior[8]. No drug treats the global picture of BPD, so medication works as a support, not a substitute[7]. Combining a well-chosen medication with therapy can help specific symptom dimensions that respond slowly to talk therapy alone[7], but the central work happens in therapy.

How Long Will I Need to Take Medication for BPD?

That depends on what the medication is for and whether it is helping, so there is no fixed answer. Because prescriptions can quietly accumulate, good care includes regular review and, when a drug is not earning its place, planned tapering[7]. Encouragingly, many BPD symptoms ease over time, with 50 to 70 percent of people no longer meeting the criteria years later[2], so medication needs often change as recovery progresses.

Get Treatment Help

If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.

Exclusive offer: 20% Off BetterHelp*

Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.

18 Sources
  1. Crotty K, Viswanathan M, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. (2024). Psychotherapies for the treatment of borderline personality disorder: a systematic review. Journal of Consulting and Clinical Psychology. https://doi.org/10.1037/ccp0000833
  2. Alvarez-Tomas I, Ruiz J, Guilera G, Bados A (2019). Long-term clinical and functional course of borderline personality disorder: a meta-analysis of prospective studies. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2018.10.010
  3. Gerolymos C, Garosi A, Boyer L, Yon DK, et al. (2026). Efficacy and safety of pharmacological treatments in borderline personality disorder: a systematic review and network meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03451-4
  4. Gartlehner G, Crotty K, Kennedy S, Edlund MJ, et al. (2021). Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. CNS Drugs. https://doi.org/10.1007/s40263-021-00855-4
  5. Stoffers J, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K (2010). Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005653.pub2
  6. Lieslehto J, Tiihonen J, Lahteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Taipale H (2023). Association of pharmacological treatments and real-world outcomes in borderline personality disorder. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.13564
  7. Bozzatello P, Rocca P, De Rosa ML, Bellino S (2020). Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1686482
  8. Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongerslev MT, et al. (2020). Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012955.pub2
  9. Pascual JC, Arias L, Soler J (2023). Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs. https://doi.org/10.1007/s40263-023-01015-6
  10. Stoffers-Winterling JM, Storebo OJ, Pereira Ribeiro J, Kongerslev MT, et al. (2022). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012956.pub2
  11. Pascual JC, Martin-Blanco A, Soler J (2021). Twenty-year trends in the psychopharmacological treatment of outpatients with borderline personality disorder: a cross-sectional naturalistic study in Spain. CNS Drugs. https://doi.org/10.1007/s40263-021-00852-7
  12. Vita A, De Peri L, Sacchetti E (2011). Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31822c1636
  13. Pereira Ribeiro J, Juul S, Kongerslev MT, Jorgensen MS, et al. (2025). Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses. British Journal of Psychiatry. https://doi.org/10.1192/bjp.2024.172
  14. Mercer D, Douglass AB, Links PS (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. Journal of Personality Disorders. https://doi.org/10.1521/pedi.2009.23.2.156
  15. Crawford MJ, Sanatinia R, Barrett B, Cunningham G, et al. (2018). The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2018.17091006
  16. Valdivieso-Jimenez G, Pino-Zavaleta DA, Campos-Rodriguez SK, Ortiz-Saavedra B, et al. (2023). Efficacy and safety of aripiprazole in borderline personality disorder: a systematic review. Psychiatric Quarterly. https://doi.org/10.1007/s11126-023-10045-8
  17. Kienast T, Stoffers J, Bermpohl F, Lieb K (2014). Borderline personality disorder and comorbid addiction: epidemiology and treatment. Deutsches Arzteblatt International. https://doi.org/10.3238/arztebl.2014.0280
  18. Leichsenring F, Fonagy P, Heim N, Kernberg OF, Leweke F, Luyten P, et al. (2024). Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. https://doi.org/10.1002/wps.21156
Written by
Jessica Miller is the Content Manager of Addiction Help

Editorial Director

Jessica Miller is the Editorial Director of Addiction Help. Jessica graduated from the University of South Florida (USF) with an English degree and combines her writing expertise and passion for helping others to deliver reliable information to those impacted by addiction. Informed by her personal journey to recovery and support of loved ones in sobriety, Jessica's empathetic and authentic approach resonates deeply with the Addiction Help community.

Reviewed by
  • Fact-Checked
  • Editor
Kent S. Hoffman, D.O. is a founder of Addiction Help

Co-Founder & Chief Medical Officer

Kent S. Hoffman, D.O. has been an expert in addiction medicine for more than 15 years. In addition to managing a successful family medical practice, Dr. Hoffman is board certified in addiction medicine by the American Osteopathic Academy of Addiction Medicine (AOAAM). Dr. Hoffman has successfully treated hundreds of patients battling addiction. Dr. Hoffman is the Co-Founder and Chief Medical Officer of AddictionHelp.com and ensures the website’s medical content and messaging quality.

Real Help. Real Recovery.

Compare centers, explore options and start your path to recovery today.

Find Treatment Now

"AddictionHelp.com is helping to make recovery available to EVERYONE!"

- Angela N.